Head to head comparison of two PET/CT imaging agents, [¹⁸F]D3FSP ([¹⁸F]P16-129) and [¹⁸F]AV45, in patients with alzheimer's disease.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2025-06-22 DOI:10.1186/s13550-025-01276-w

David Alexoff, Dean F Wong, Hiroto Kuwabara, Robert F Dannals, Karl Ploessl, Hank F Kung

{"title":"Head to head comparison of two PET/CT imaging agents, [18F]D3FSP ([18F]P16-129) and [18F]AV45, in patients with alzheimer's disease.","authors":"David Alexoff, Dean F Wong, Hiroto Kuwabara, Robert F Dannals, Karl Ploessl, Hank F Kung","doi":"10.1186/s13550-025-01276-w","DOIUrl":null,"url":null,"abstract":"Background: A new β-amyloid (Aβ) targeting radiotracer, [18F]D3FSP ([18F]P16-129), for diagnosis of Alzheimer's disease (AD) is reported. This radiotracer is a deuterated N-methyl derivative of Amyvid (AV-45, florbetapir f18) which was FDA-approved in 2013. Deuteration may alter a tracer's PK such that imaging performance is improved. A head-to-head comparison between these two imaging agents was conducted in AD patients. A separate biodistribution study was conducted on six healthy subjects, and radiation dosimetry estimation was obtained.Results: Eight patients, clinically diagnosed with Alzheimer's disease, had an average age of 61.1 ± 10.0 years, and an average MMSE score of 21 ± 4. Each patient underwent paired 90-minute dynamic PET/CT scans separately within a few weeks (323 ± 31 MBq of [18F]D3FSP or [18F]AV45; florbetapir f18). SUVR (50-70 min) and Distribution Volume Ratio (DVR) of 43 brain regions were evaluated. The average SUVR across cortical gray matter was 1.65 ± 0.21 for [18F]AV45 and 1.65 ± 0.23 for [18F]D3FSP, while global DVRs were 1.36 ± 0.14 and 1.37 ± 0.13 for [18F]AV45 and [18F]D3FSP respectively. Strong correlations (R2 = 0.8-0.9) were observed between tracers for both SUVR and DVR, with slopes of ~ 0.9 (SUVR) and ~ 1 (DVR). No image artifacts or confounds influenced the visual interpretation of [18F]D3FSP compared to [18F]AV45.Conclusions: Results showed no difference between [18F]D3FSP and [18F]AV45 and no benefit of deuteration at the N-methyl site. Even so, [18F]D3FSP may be a useful alternative for PET/CT imaging of Aβ deposits in the brain as its binding characteristics were very similar to its non-deuterated analog, the FDA-approved drug [18F]AV45.Trial registration: Clinicaltrials.org, NCT03902548. Registered 01/07/2018.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"77"},"PeriodicalIF":3.1000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183142/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01276-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: A new β-amyloid (Aβ) targeting radiotracer, [¹⁸F]D3FSP ([¹⁸F]P16-129), for diagnosis of Alzheimer's disease (AD) is reported. This radiotracer is a deuterated N-methyl derivative of Amyvid (AV-45, florbetapir f18) which was FDA-approved in 2013. Deuteration may alter a tracer's PK such that imaging performance is improved. A head-to-head comparison between these two imaging agents was conducted in AD patients. A separate biodistribution study was conducted on six healthy subjects, and radiation dosimetry estimation was obtained.

Results: Eight patients, clinically diagnosed with Alzheimer's disease, had an average age of 61.1 ± 10.0 years, and an average MMSE score of 21 ± 4. Each patient underwent paired 90-minute dynamic PET/CT scans separately within a few weeks (323 ± 31 MBq of [¹⁸F]D3FSP or [¹⁸F]AV45; florbetapir f18). SUVR (50-70 min) and Distribution Volume Ratio (DVR) of 43 brain regions were evaluated. The average SUVR across cortical gray matter was 1.65 ± 0.21 for [¹⁸F]AV45 and 1.65 ± 0.23 for [¹⁸F]D3FSP, while global DVRs were 1.36 ± 0.14 and 1.37 ± 0.13 for [¹⁸F]AV45 and [¹⁸F]D3FSP respectively. Strong correlations (R² = 0.8-0.9) were observed between tracers for both SUVR and DVR, with slopes of ~ 0.9 (SUVR) and ~ 1 (DVR). No image artifacts or confounds influenced the visual interpretation of [¹⁸F]D3FSP compared to [¹⁸F]AV45.

Conclusions: Results showed no difference between [¹⁸F]D3FSP and [¹⁸F]AV45 and no benefit of deuteration at the N-methyl site. Even so, [¹⁸F]D3FSP may be a useful alternative for PET/CT imaging of Aβ deposits in the brain as its binding characteristics were very similar to its non-deuterated analog, the FDA-approved drug [¹⁸F]AV45.

Trial registration: Clinicaltrials.org, NCT03902548. Registered 01/07/2018.

查看原文本刊更多论文

两种PET/CT显像剂[18F]D3FSP （[18F]P16-129）和[18F]AV45在阿尔茨海默病患者中的正面比较

背景：报道了一种新的β-淀粉样蛋白（Aβ）靶向放射性示踪剂[18F]D3FSP （[18F]P16-129）用于阿尔茨海默病（AD）的诊断。该放射性示踪剂是Amyvid （AV-45, florbetapir f18）的氘化n -甲基衍生物，于2013年获得fda批准。氘化可以改变示踪剂的PK，从而改善成像性能。在AD患者中对这两种显像剂进行了正面比较。对6名健康受试者进行了单独的生物分布研究，并获得了辐射剂量学估计。结果：8例临床诊断为阿尔茨海默病的患者，平均年龄61.1±10.0岁，平均MMSE评分21±4分。每位患者在几周内分别进行配对的90分钟动态PET/CT扫描(323±31 MBq的[18F]D3FSP或[18F]AV45；florbetapir f18)。评估43个脑区SUVR （50 ~ 70 min）和分布容积比（DVR）。[18F]AV45和[18F]D3FSP的皮质灰质平均SUVR分别为1.65±0.21和1.65±0.23，而[18F]AV45和[18F]D3FSP的整体dvr分别为1.36±0.14和1.37±0.13。在SUVR和DVR示踪剂之间观察到强相关性（R2 = 0.8-0.9），斜率为~ 0.9 （SUVR）和~ 1 （DVR）。与[18F]AV45相比，[18F]D3FSP没有图像伪影或混淆影响视觉解释。结论：结果显示[18F]D3FSP与[18F]AV45之间没有差异，n -甲基位置的氘化没有好处。尽管如此，[18F]D3FSP可能是脑内a β沉积的PET/CT成像的有用替代方案，因为其结合特性非常类似于其非氘化类似物，fda批准的药物[18F]AV45。试验注册：Clinicaltrials.org, NCT03902548。01/07/2018注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.